A Phase 1 interventional study of 0.1% QY211 Gel or placebo and 0.3% QY211 Gel or placebo in Atopic Dermatitis, sponsored by E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-06.
Sponsored by E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 207 studies in Dermatitis, Atopic with a site in China — 65 open to participants now, 83 under way, 29 of them phase 3. Dermatitis, Atopic · China.
Among the 207 studies in Dermatitis, Atopic with a site in China, this one is the 154th largest by planned enrollment of the 191 interventional ones that give a count, is one of 39 that started in 2023, is one of 39 in phase 1, and was the 69th registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →65 of the 207 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:
Galderma R&D · Sites in China
Ages 12+
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Sites in China
Ages 18–75
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Sites in China
Ages 2–11
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18–75
QuantX Biosciences, Inc. · Sites in China
Ages 18 mo–65 yrs · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
207 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 54 · Phase 2 76 · Phase 3 63 · Phase 4 5
First in 2011; this study’s year is marked. 39 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 56 is below the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 163 across the 191 interventional studies, 472 across the 16 observational. Of the 114 that completed or were terminated, 22 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
184 of 207 have an industry lead sponsor. The 10 most frequent:
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. has 4 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
27 of the studies in Dermatitis, Atopic with a site in China that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06775860Phase 3Beijing InnoCare Pharma Tech Co., Ltd.ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis | 2026-11-25 |
| NCT07540442Phase 3Shanghai Mabgeek Biotech.Co.LtdA Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis | 2027-01-05 |
| NCT07106372Phase 3Keymed Biosciences Co.LtdA Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | 2027-02 |
| NCT06880276Phase 3Qilu Pharmaceutical Co., Ltd.Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis | 2027-03 |
| NCT07386743Phase 3Jiangsu Genscend Biopharmaceutical Co., LtdA Phase III Study of GS101 Injection to Dupixent® | 2027-04 |
Add all 27 to your calendar (.ics) → With an account.
Among the 207 studies in Dermatitis, Atopic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase Ia/Ib,Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of Single and Multiple Topical Doses of QY211 Gel in Healthy Chinese Subjects and Patients with Mild to Moderate Atopic Dermatitis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 1
Part 2
Exclusion Criteria:
Part 1
Part 2
Patients with the following cardiac abnormalities:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6 subjects use 0.8% QY211 Gel,2 subject uses 0.8% QY211 placebo ,11days(Day1 QD,Day4-Day10 BID,Day11 QD ).
Drug: 0.8% QY211 Gel or placebo
6 subjects use 0.8% QY211 Gel,2 subject uses 0.8% QY211 placebo ,11days(Day1 QD,Day4-Day10 BID,Day11 QD ).
Drug: 1.5% QY211 Gel or placebo
6 subjects use 0.8% QY211 Gel,2 subject uses 0.8% QY211 placebo ,11days(Day1 QD,Day4-D10 BID,Day11 QD ).
Drug: 1.5% QY211 Gel or placebo
6 subjects use 0.1% QY211 Gel,2 subject uses 0.1% QY211 placebo ,29days(Day1-Day28 BID,Day29 QD).
Drug: 0.1% QY211 Gel or placebo
6 subjects use 0.3% QY211 Gel,2 subject uses 0.3% QY211 placebo ,29days(Day1-Day28 BID,Day29 QD).
Drug: 0.3% QY211 Gel or placebo
6 subjects use 0.3% QY211 Gel,2 subject uses 0.3% QY211 placebo ,29days(Day1-Day28 BID,Day29 QD).
Drug: 0.8% QY211 Gel or placebo
6 subjects use 0.3% QY211 Gel,2 subject uses 0.3% QY211 placebo ,29days(Day1-Day28 BID,Day29 QD).
Drug: 1.5% QY211 Gel or placebo
QY211 Gel or placebo topical applied to skin
QY211 Gel or placebo topical applied to skin
QY211 Gel or placebo topical applied to skin
QY211 Gel or placebo topical applied to skin
Part1:Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Time frame: Day 1 to Day 13
Part1:Number of Participants With Clinical Laboratory Abnormalities
A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from baseline and occurring after the first dose of study drug
Time frame: Day 3 to Day 13
Part1:Number of Participants With Clinically Significant Changes Form Baseline in Physical Examination
Time frame: Day 3 to Day 13
Part1:Number of Participants With Clinically Significant Treatment-emergent Electrocardiogram (ECG) Findings
ECG data will be monitored
Time frame: Day 3 to Day 13
Part 1:Number of Participants With Clinically Significant Changes Form Baseline in Vital Signs
Time frame: Day 1 to Day 13
Part 1:Severity of local skin irritation
Skin irritation response assessment recording method: ① subjective symptoms: including itching, pain, or burning sensation, evaluated according to the 4-level method: 0=none; 1=mild, without affecting daily life and sleep; 2=Moderate, affecting daily life but not sleep; 3=Severe, affecting sleep.The signs of skin lesions include erythema, papules, edema, blisters, bullae, exudates, pustules, erosion, exudates, ulcers, hypertrophy, desquamation, etc., which can be evaluated according to the 4-level method: 0=none; 1=Mild, with only blurred erythema, no edema (skin lesions not palpable), and papules; 2=Moderate, clear erythema with edema (skin lesions can be touched) and papules; "3=Severe, with blisters, bullae, exudates or pustules, erosion, exudates or ulcers.
Time frame: Day 1 to Day 13
Part 2:Number of Participants With Adverse Events (AEs) and Serious Adverse Events
An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Time frame: Day 1 to Day 31
Part2:Number of Participants With Clinical Laboratory Abnormalities
A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from baseline and occurring after the first dose of study drug
Time frame: Day 8 to Day 29
Part2:Number of Participants With Clinically Significant Changes Form Baseline in Physical Examination
Time frame: Day 8 to Day 29
Part2:Number of Participants With Clinically Significant Treatment-emergent Electrocardiogram (ECG) Findings
ECG data will be monitored
Time frame: Day 8 to Day 29.
Part 2:Number of Participants With Clinically Significant Changes Form Baseline in Vital Signs
Time frame: Day 8 to Day 30
Rate of change from baseline in Eczema Area and Severity Index (EASI) in patients(part 2 only)
EASI quantifies severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema, induration /papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs ) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (0 to 9%), 2 (10 to 29%), 3 (30 to 49%), 4 (50 to 69%), 5 (70 to 89%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.
Time frame: Up to 4 weeks
Proportion of patients with at least a 2-point improvement in IGA score from baseline(part 2 only)
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).Proportion of patients with Investigator's Global Assessment (IGA) score of 0 or 1 and an improvement of at least 2 points in IGA score from baseline at 1, 2, 3 and 4 weeks after treatment.
Time frame: Up to 4 weeks
Percentage of Participants Achieving >=50%/75%/90% Improvement From Baseline in Eczema Area and Severity Index (EASI-50/EASI-75/EASI-90) Response(part2 only)
EASI quantifies severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs ) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (0 to 9%), 2 (10 to 29%), 3 (30 to 49%), 4 (50 to 69%), 5 (70 to 89%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.
Time frame: Up to 4 weeks
Change from baseline in Peak daily Pruritus NRS score (PP-NRS) (part 2 only)
Change from baseline in Peak daily Pruritus NRS score (PP-NRS) during treatment.Using a 0 to 10 point scale, 0 represents "" no itching "" and 10 represents "" worst itch imaginable "",Rating the degree of itchiness experienced in the past 24 hours.
Time frame: Up to 29 days
Rate of change from baseline in SCORAD score (part 2 only)
SCORAD (Severity Scoring of Atopic Dermatitis) Change from Baseline to Week 8 of atopic dermatitis lesion as measured by the Scoring of Atopic Dermatitis (SCORAD). SCORAD is a composite severity index comprising a) the amount/extent of body area affected; b) 2 subjective symptom of pruritus (0-10 points) and sleep disturbance measured (0-10 points); and c) 6 disease intensity assessments \[Dryness/Scaling, Erythema, Excoriation, Induration/Papulation, Lichenification and Oozing/ Weeping/Crusting, each grades from 0 (None) to 3 (Severe). A SCORAD score ranges from 0 (No AD present) to 103.
Time frame: Up to 4 weeks
Change from baseline in total score of Dermal Quality of Life Index Questionnaire (DLQI) (part 2 only)
The DLQI is a dermatology-specific quality of life (QOL) instrument designed to assess impact of disease on a participants QOL. It is a 10-item questionnaire that, in addition to evaluating overall, QOL can be used to assess 6 different aspects: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships and treatment. Questions scored on a 4-point Likert scale: 0 (not relevant), 1 (a little), 2 (a lot), and 3 (very much). Scores of individual items (0-3) were added to yield a total score (0-30); higher score = greater impairment of participants QOL.
Time frame: Up to 4 weeks
Rate of change from baseline in atopic dermatitis in BSA(part 2 only)
Rate of change from baseline in atopic dermatitis in BSA at Weeks 1, 2, 3, and 4 postdose.
Time frame: Up to 4 weeks
Tmax of QY211-Single and Multiple Dose Drugs
Time of maximum concentration(single Dose and Steady state PK)
Time frame: Up to 29 days
Cmax of QY211-Single and Multiple Dose Drugs
Maximum observed plasma concentration(single Dose and Steady state PK)
Time frame: Up to 29 days
t1/2 of QY211-Single and Multiple Dose Drugs
The time it takes for the blood concentration of the drug to drop by half from the highest value in the body(single Dose and Steady state PK)
Time frame: Up to 29 days
AUC QY211-Single and Multiple Dose Drugs
Area under the plasma concentration-time curve from time zero to the last quantifiable concentration(single Dose and Steady state PK)
Time frame: Up to 29 days
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Oct 2024, 19 months after the start.
Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 19 months is above that.
Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.